Derek J. Maetzold Sells 22,639 Shares of Castle Biosciences, Inc. (NASDAQ:CSTL) Stock

Castle Biosciences, Inc. (NASDAQ:CSTL) insider Derek J. Maetzold sold 22,639 shares of the company’s stock in a transaction on Friday, March 7th. The shares were sold at an average price of $20.12, for a total value of $455,496.68. Following the completion of the transaction, the insider now directly owns 80,465 shares in the company, valued at approximately $1,618,955.80. This represents a 21.96 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Castle Biosciences Stock Performance

Shares of Castle Biosciences stock opened at $19.63 on Thursday. The company has a current ratio of 7.78, a quick ratio of 7.64 and a debt-to-equity ratio of 0.02. The company has a market cap of $549.78 million, a PE ratio of 98.15 and a beta of 0.98. The company has a 50 day moving average of $26.17 and a 200-day moving average of $28.77. Castle Biosciences, Inc. has a 1-year low of $16.97 and a 1-year high of $35.84.

Analyst Ratings Changes

A number of equities analysts recently commented on CSTL shares. Robert W. Baird raised their price target on shares of Castle Biosciences from $36.00 to $37.00 and gave the stock an “outperform” rating in a research report on Friday, February 28th. Stephens reissued an “overweight” rating and set a $41.00 price target on shares of Castle Biosciences in a research report on Thursday, January 2nd. Seven analysts have rated the stock with a buy rating, According to data from MarketBeat, Castle Biosciences has a consensus rating of “Buy” and a consensus target price of $40.00.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the company. Connor Clark & Lunn Investment Management Ltd. increased its stake in shares of Castle Biosciences by 147.4% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 165,458 shares of the company’s stock valued at $4,719,000 after purchasing an additional 98,571 shares during the last quarter. Barclays PLC boosted its stake in Castle Biosciences by 310.7% in the third quarter. Barclays PLC now owns 52,301 shares of the company’s stock valued at $1,491,000 after buying an additional 39,567 shares in the last quarter. JPMorgan Chase & Co. boosted its stake in Castle Biosciences by 165.2% in the third quarter. JPMorgan Chase & Co. now owns 69,409 shares of the company’s stock valued at $1,980,000 after buying an additional 43,241 shares in the last quarter. GSA Capital Partners LLP bought a new position in Castle Biosciences in the third quarter valued at about $1,478,000. Finally, Charles Schwab Investment Management Inc. raised its stake in Castle Biosciences by 16.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 274,761 shares of the company’s stock worth $7,836,000 after acquiring an additional 39,417 shares in the last quarter. 92.60% of the stock is currently owned by institutional investors and hedge funds.

Castle Biosciences Company Profile

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.